Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.02.2022 | Case report

AZD-1222

Cutaneous lymphocytic vasculitis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Ungari M, et al. Cutaneous Lymphocytic Vasculitis after Administration of the Second Dose of AZD1222 (Oxford-AstraZeneca) Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination: Casuality or Causality?. American Journal of Dermatopathology 44: 80-82, No. 1, Jan 2022. Available from: URL: http://doi.org/10.1097/DAD.0000000000002104 Ungari M, et al. Cutaneous Lymphocytic Vasculitis after Administration of the Second Dose of AZD1222 (Oxford-AstraZeneca) Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination: Casuality or Causality?. American Journal of Dermatopathology 44: 80-82, No. 1, Jan 2022. Available from: URL: http://​doi.​org/​10.​1097/​DAD.​0000000000002104​
Metadaten
Titel
AZD-1222
Cutaneous lymphocytic vasculitis: case report
Publikationsdatum
01.02.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-10505-3

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Propofol